115 related articles for article (PubMed ID: 17052612)
21. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
[TBL] [Abstract][Full Text] [Related]
22. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies.
Osapay G; Prokai L; Kim HS; Medzihradszky KF; Coy DH; Liapakis G; Reisine T; Melacini G; Zhu Q; Wang SH; Mattern RH; Goodman M
J Med Chem; 1997 Jul; 40(14):2241-51. PubMed ID: 9216843
[TBL] [Abstract][Full Text] [Related]
23. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
[TBL] [Abstract][Full Text] [Related]
24. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
Stolz B; Weckbecker G; Smith-Jones PM; Albert R; Raulf F; Bruns C
Eur J Nucl Med; 1998 Jul; 25(7):668-74. PubMed ID: 9662587
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
26. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
[TBL] [Abstract][Full Text] [Related]
27. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
Smith-Jones PM; Bischof C; Leimer M; Gludovacz D; Angelberger P; Pangerl T; Peck-Radosavljevic M; Hamilton G; Kaserer K; Kofler A; Schlangbauer-Wadl H; Traub T; Virgolini I
Endocrinology; 1999 Nov; 140(11):5136-48. PubMed ID: 10537142
[TBL] [Abstract][Full Text] [Related]
28. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
[TBL] [Abstract][Full Text] [Related]
29. Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.
Waser B; Cescato R; Tamma ML; Maecke HR; Reubi JC
Eur J Pharmacol; 2010 Oct; 644(1-3):257-62. PubMed ID: 20643121
[TBL] [Abstract][Full Text] [Related]
30. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.
Vallabhajosula S; Moyer BR; Lister-James J; McBride BJ; Lipszyc H; Lee H; Bastidas D; Dean RT
J Nucl Med; 1996 Jun; 37(6):1016-22. PubMed ID: 8683294
[TBL] [Abstract][Full Text] [Related]
34. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
[TBL] [Abstract][Full Text] [Related]
35. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
Ginj M; Hinni K; Tschumi S; Schulz S; Maecke HR
J Nucl Med; 2005 Dec; 46(12):2097-103. PubMed ID: 16330576
[TBL] [Abstract][Full Text] [Related]
36. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
Ferone D; van Hagen MP; Kwekkeboom DJ; van Koetsveld PM; Mooy DM; Lichtenauer-Kaligis E; Schönbrunn A; Colao A; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2000 Apr; 85(4):1719-26. PubMed ID: 10770220
[TBL] [Abstract][Full Text] [Related]
38. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
39. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.
Waser B; Tamma ML; Cescato R; Maecke HR; Reubi JC
J Nucl Med; 2009 Jun; 50(6):936-41. PubMed ID: 19443580
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
